Novartis acquired MorphoSys for $2.9B. Barbara Krebs-Pohl joined the CASI Board of Directors and previously served as CBO at MorphoSys.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis acquired MorphoSys for $2.9B. Barbara Krebs-Pohl joined the CASI Board of Directors and previously served as CBO at MorphoSys.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Antibe Therapeutics and Morphosys are both companies operating in the pharmaceutical development sector.Sub-event
Novartis completes acquisition of MorphoSys; Krebs-Pohl joins CASI board.1 source
Keep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Morphosys
German biopharmaceutical company
Nothing else this week.
-
CASI Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
Related events
- Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
- Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
- Novartis' trial results are impacting Royalty Pharma's investment decisions.
Coverage
Newest first; wire copies grouped- ACCESS NewswireCASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors - Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships,
- Unknown outlet